Selected article for: "binding model and control antibody"
Author: M. Gordon Joyce; Rajeshwer S. Sankhala; Wei-Hung Chen; Misook Choe; Hongjun Bai; Agnes Hajduczki; Lianying Yan; Spencer L. Sterling; Caroline E. Peterson; Ethan C. Green; Clayton Smith; Natalia de Val; Mihret Amare; Paul Scott; Eric D. Laing; Christopher C. Broder; Morgane Rolland; Nelson L. Michael; Kayvon Modjarrad
Title: A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein
  • Document date: 2020_3_17
    • ID: ebbzx8yr_54
    Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https: //doi.org/10.1101 //doi.org/10. /2020 to SARS-CoV-2 RBD measured by biolayer interferometry. Kinetic constants were determined were calculated using a minimum of four dilutions of the RBD and fitted using a 1:1 binding model. C,D, Competition binding of antibodies CR3022 and 240CD to SARS-CoV-2 RBD. CR3022 or control antibody was allowed to bind to SARS-COV-2 pri.....
    Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https: //doi.org/10.1101 //doi.org/10. /2020 to SARS-CoV-2 RBD measured by biolayer interferometry. Kinetic constants were determined were calculated using a minimum of four dilutions of the RBD and fitted using a 1:1 binding model. C,D, Competition binding of antibodies CR3022 and 240CD to SARS-CoV-2 RBD. CR3022 or control antibody was allowed to bind to SARS-COV-2 prior to binding to 240CD or vice-versa. E SARS-CoV-2 RBD was sequentially bound by antibodies CR3022 or 240CD followed by soluble human ACE2 receptor. F SARS-CoV reactive antibodies were assessed for binding to bat SARS-related CoV Rs4784 and Rs4231 S glycoproteins. author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under

    Search related documents:
    Co phrase search for related documents
    • binding model and competition binding: 1
    • binding model and control antibody: 1, 2
    • binding model and SARS bind: 1, 2, 3, 4, 5
    • biolayer interferometry and competition binding: 1, 2, 3
    • biolayer interferometry and control antibody: 1
    • biolayer interferometry and Government work: 1, 2, 3
    • biolayer interferometry and kinetic constant: 1
    • biolayer interferometry and SARS bind: 1
    • competition binding and control antibody: 1, 2
    • competition binding and SARS bind: 1, 2, 3, 4, 5, 6
    • control antibody and reactive antibody: 1
    • control antibody and SARS bind: 1
    • reactive antibody and SARS bind: 1